Provided by Tiger Trade Technology Pte. Ltd.

WisdomTree BioRevolution Fund

23.68
+0.04760.20%
Post-market: 23.680.00000.00%16:10 EDT
Volume:2K
Turnover:58.12K
Market Cap:4.74M
PE:- -
High:23.71
Open:23.71
Low:23.48
Close:23.63
52wk High:24.29
52wk Low:15.67
Shares:200.00K
Float Shares:200.00K
Volume Ratio:1.89
T/O Rate:1.23%
Dividend:0.77
Dividend Rate:3.26%
ROE:--
ROA:--
PB:--
PE(LYR):- -

Loading ...

Novartis Strikes up to $7.8 Billion mRNA Deal with China's Abogen

Reuters
·
Oct 02

Why Did Moderna Stock Gain (MRNA) in After-Hours Trading on Thursday?

TIPRANKS
·
Oct 02

Moderna to Join Nasdaq 100, Replacing Warner Bros Discovery

Reuters
·
Oct 02

Rpt-NASDAQ - Moderna to Join NASDAQ-100 Index Replacing Warner Bros. Discovery on October 9, 2026

THOMSON REUTERS
·
Oct 02

Sector Update: Healthcare

MT Newswires Live
·
Oct 02

Trump Medicare Drug Pricing Model May Apply to Only Four Companies After Exemptions

Reuters
·
Oct 02

Eli Lilly's Obesity Data Support Broader Portfolio Beyond Tirzepatide, UBS Says

MT Newswires Live
·
Oct 02

Eli Lilly (LLY) Ends Cancer Development Deal with Foghorn Therapeutics

TIPRANKS
·
Oct 01

Twist Bioscience is Maintained at Buy by Guggenheim

Dow Jones
·
Oct 01

Analysts Have Conflicting Sentiments on These Healthcare Companies: Sanofi (OtherSNYNF), Sagimet Biosciences, Inc. Class A (SGMT) and Eli Lilly & Co (LLY)

TIPRANKS
·
Oct 01

Moderna Stock Gets Sell Call As Oncology Hopes Face Valuation Test

Simply Wall St.
·
Oct 01

Twist Bioscience price target raised to $212 from $107 at Guggenheim

TIPRANKS
·
Oct 01

Foghorn Therapeutics Slashes Jobs After Ending Cancer Drug Trials with Ely Lilly

Dow Jones
·
Oct 01

Lilly Says Foundayo Cuts Predicted 10-Year Type 2 Diabetes Risk 57% in Attain-1 Post-Hoc Analysis

Reuters
·
Oct 01

Eli Lilly - Foundayo 17.2 Mg Associated with 57% Reduction in Diabetes Risk, 18% in Cardiovascular Risk Versus Placebo

Reuters
·
Oct 01

Eli Lilly - Foundayo Associated with Reduced Predicted Long-Term Risk of Type 2 Diabetes and Cardiovascular Disease

THOMSON REUTERS
·
Oct 01

The Next Frontier for Obesity Drugs Isn't How Much Weight You Lose, but What Kind

Dow Jones
·
Oct 01

Eli Lilly Says Foundayo Drug Helped Patients Lose Weight in Phase 3 Trial

Dow Jones
·
Oct 01

Eli Lilly’s Foundayo shows cardiovascular safety in type 2 diabetes study

TIPRANKS
·
Oct 01

Lilly's Oral Glp-1, Foundayo (Orforglipron), Demonstrated Cardiovascular Safety Alongside Sustained A1c Reduction and Weight Loss in Its Largest and Longest Type 2 Diabetes Study

THOMSON REUTERS
·
Oct 01